Francesco La Rocca

Dr. Francesco La Rocca

Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 December 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
LLLuciana De Luca
Luciana De Luca
STStefania Trino
Stefania Trino
Ilaria LaurenzanaIlaria Laurenzana
Ilaria Laurenzana
VSVittorio Simeon
Vittorio Simeon
GCGiovanni Calice
Giovanni Calice
PMPellegrino Musto
Pellegrino Musto
MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation

19 October 2016 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
ACAntonella Caivano
Antonella Caivano
FRFrancesco La Rocca
Francesco La Rocca
VSVittorio Simeon
Vittorio Simeon
MGMarco Girasole
Marco Girasole
SDSimone Dinarelli
Simone Dinarelli
PMPellegrino Musto
Pellegrino Musto

Verified
Journal Article
Open access
PDF file
SRSabino Russi
Sabino Russi
HVHenu Kumar Verma
Henu Kumar Verma
SLSimona Laurino
Simona Laurino
PMPellegrino Mazzone
Pellegrino Mazzone
GSGiovanni Storto
Giovanni Storto
VRVitalba Ruggieri
Vitalba Ruggieri
Despite the significant recent advances in clinical practice, gastric cancer (GC) represents a leading cause of cancer-related deaths in the world. In fact, occurrence of chemo-resistance still remains a daunting hindrance to effectiveness of the current approach to GC therapy. There is accumulating evidence that a plethora of cellular and molecular factors is implicated in drug-induced phenotypical switching of GC cells. Among them, epithelial-mesenchymal transition (EMT), autophagy, drug detoxification, DNA damage response and drug target alterations, have been reported as major determinants. Intriguingly, resistant GC phenotype may be the result of GC cell-induced tumor microenvironment (TME) remodeling, which is currently emerging as a key player in promoting drug resistance and overcoming cytotoxic effects of drugs. In this review, we discuss the possible mechanisms of drug resistance and their involvement in determining current GC therapies failure.

26 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
SRSabino Russi
Sabino Russi
GCGiovanni Calice
Giovanni Calice
VRVitalba Ruggieri
Vitalba Ruggieri
SLSimona Laurino
Simona Laurino
FRFrancesco La Rocca
Francesco La Rocca
PZPietro Zoppoli
Pietro Zoppoli
Gastric cancer (GC) is a leading cause of cancer-related deaths in the world. Molecular heterogeneity is a major determinant for the clinical outcomes and an exhaustive tumor classification is currently missing. Histologically normal tissue adjacent to the tumor (NAT) is commonly used as a control in cancer studies, nevertheless a recently published paper described the unique characteristics of the NAT in several tumor types. Little is known about the global gene expression profile of gastric NAT (gNAT) which could be an effective tool for a more realistic definition of GC molecular signature. Here, we integrated data of 512 samples from the Genotype-Tissue Expression project (GETx) and The Cancer Genome Atlas (TCGA) to analyze the transcriptome of healthy gastric tissues, gNAT, and GC samples. We validated TCGA-GETx data mining through inHouse gNAT and GC expression dataset. Differential gene expression together with pathway enrichment analyses, indeed, led to different results when using the gNAT or the healthy tissue as control. Based on our analyses, gNAT showed a peculiar gene signature and biological features, like the estrogen receptor pathways activation, suggesting a molecular behavior partially different from both healthy and GC tissues. Therefore, using gNAT as healthy control tissue in the characterization of tumor associated biological processes and pathways could lead to suboptimal results.

14 October 2016 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
LLLuciana De Luca
Luciana De Luca
GDGiovanni D’arena
Giovanni D’arena
VSVittorio Simeon
Vittorio Simeon
STStefania Trino
Stefania Trino
Ilaria LaurenzanaIlaria Laurenzana
Ilaria Laurenzana
PMPellegrino Musto
Pellegrino Musto
Microvescicles (MV) are shedding particles released by normal and neoplastic cells, whose levels in biological fluids highlight their potential role as disease biomarkers and therapeutic targets. By analyzing 131 newly diagnosed chronic lymphocytic leukemia (CLL), we found that the absolute number of serum CLL MV was significantly higher than in controls, in particular in advanced stages of disease. In addition, CD19 + and CD37+, B-cell derived MV, significantly correlated with high tumor burden. Absolute MV number cutoff selected by ROC analysis distinguished Rai stage 0 patients with shorter time to treatment (TTT) from those with more stable disease. Likewise, in the entire cohort, two groups of patients with different overall survival (OS) and different TTT were identified. At multivariate analysis, serum MV independently predicted for OS (along with Rai stage) and TTT (along with Rai stage, lymphocytes and CD38). In conclusion, circulating MV represent a new potential prognostic biomarker in CLL.